###### Significance of this study

What is already known about this subject?
=========================================

-   Use of insulin therapy in patients with type 2 diabetes creates a risk of developing (severe) hypoglycemia.

-   Recurrent (severe) hypoglycemia may lead to the development of impaired awareness of hypoglycemia (IAH).

-   The prevalence of IAH in patients with type 1 diabetes is around 25%; however, less is known about the prevalence of IAH in people with type 2 diabetes.

What are the new findings?
==========================

-   In this nationwide cohort, the prevalence of IAH in patients with type 2 diabetes on insulin therapy was almost 10%.

-   The prevalence of severe hypoglycemia in this cohort was more than 30%.

-   IAH and severe hypoglycemia occur in patients irrespective of whether they are managed in primary care or not.

How might these results change the focus of research or clinical practice?
==========================================================================

-   Greater awareness for IAH and severe hypoglycemia in people with type 2 diabetes on insulin is needed.

-   Appropriate education to reduce the risk of hypoglycemia in these patients seems warranted

Introduction {#s1}
============

Insulin-related hypoglycemia is a common adverse effect of insulin therapy. Recent data show almost 98 000 visits to the emergency department and 30 000 hospitalizations in the USA per year due to insulin-related hypoglycemia.[@R1] Over 75% of these emergency department visits occur in middle-aged or elderly people, suggesting that most of these people suffer from type 2 diabetes.

The reported prevalence of hypoglycemic events in people with type 2 diabetes on insulin therapy is highly variable and partly determined by the duration and intensity of insulin therapy. Previous studies have shown that people with type 2 diabetes treated with insulin for \<2 years experience on average four non-severe episodes per person-year, whereas those treated for \>5 years experience 10 episodes per person-year.[@R2] Similarly, severe hypoglycemia, defined as an event requiring external help to recover, rarely occurs in the first years after the start of insulin therapy but becomes more common during later years.[@R4] One report estimated the overall prevalence of severe hypoglycemia in type 2 diabetes treated with insulin in secondary care at 0.28 episodes per patient per year.[@R6]

Recurrent exposure to hypoglycemia can induce a process of habituation leading to impaired awareness of hypoglycemia (IAH). This syndrome increases the risk for developing severe hypoglycemia considerably,[@R5] yet reflects a functional defect that can be reversed by strict avoidance of hypoglycemia.[@R7] IAH has been well described in type 1 diabetes and affects approximately 25% of people with type 1 diabetes, a percentage that appears relatively stable across different cohorts and over time.[@R10] Less information is available concerning the prevalence of IAH in type 2 diabetes, with reported prevalence of IAH in single-centre surveys varying between 7% and 46% among those treated with insulin.[@R5] The aim of this study was to assess the prevalence and determinants of IAH and severe hypoglycemia in a large nationwide cohort of patients with insulin-treated type 2 diabetes.

Research Design and Methods {#s2}
===========================

Study design {#s2-1}
------------

The Dutch Diabetes Pearl is an observational cohort study of people with type 2 diabetes in the Netherlands. The participants are managed in primary care (in the Hoorn area or the region of Maastricht) or in secondary and tertiary care in seven of the total eight academic medical centers across the country. Details on the design of the Dutch Diabetes Pearl have been published previously.[@R16] The study was approved by Institutional Review Boards of all the participating medical centers. Patients were excluded if they were unable to understand and write the Dutch language.

Study population {#s2-2}
----------------

Patients were enrolled in the Dutch Diabetes Pearl cohort between 2009 and 2015.[@R16] For this analysis, we only included patients with type 2 diabetes who were treated with insulin. We excluded patients that did not fill in the Clarke questionnaire, including all participants from one center that did not administer this questionnaire ([figure 1](#F1){ref-type="fig"}).

![Flow diagram showing patient selection.](bmjdrc-2019-000935f01){#F1}

Study procedure {#s2-3}
---------------

After signing informed consent, data were collected following standard operational procedures. Briefly, we collected the following data in the Diabetes Pearl: demographics, physical examinations, laboratory measurements and several questionnaires including the validated Dutch version of the Clarke questionnaire (see below for details).[@R16]

Study outcomes {#s2-4}
--------------

The primary outcome of this study was the prevalence of IAH in people with type 2 diabetes on insulin therapy. All participants were therefore asked to complete the clamp-validated Dutch modified translation of the Clarke questionnaire.[@R17] This questionnaire consists of a validated translation of the original five questions; two questions on symptoms of hypoglycemia, one on the ability to recognize hypoglycemia based on symptoms, one on the level of blood glucose when experiencing hypoglycemic symptoms, and two questions on the occurrence of severe hypoglycemia, one relating to the requirement of a third party, one relating to the need for medical assistance, both in the past year. Each question was awarded with one or zero points, with three or more out of five points indicating IAH. Severe hypoglycemia was defined by a positive answer to one of both questions regarding severe hypoglycemia. Missing data on the Clarke questionnaire were imputed with 0 (having no symptoms) if patients filled in at least one answer.

Other measurements {#s2-5}
------------------

We also assessed a range of demographic and clinical factors including age, diabetes duration, hemoglobin A1c (HbA~1c~), ethnicity, smoking, alcohol consumption, having a partner and level of education, to identify potential risk factors, as described below.

Hospital information systems at all recruitment centers were used to collect information on date of birth and gender. Ethnicity was estimated as described earlier.[@R19] Education level was self-reported. A high educational level was defined as higher professional education or university education. Information on alcohol consumption and smoking were obtained by questionnaire; smoking was categorized as never, former and current smoking. Body mass index (BMI) was defined as a person's weight (kilograms) divided by square of height (meters). Participants brought all their medication or a list from the pharmacy to the hospital so that medication use (eg, beta-blockers and psychoactive drugs) could be reported accurately. Drug use was divided into three arbitrary categories; no polypharmacy (0--4 drugs), moderate polypharmacy (5--9 drugs) and pronounced polypharmacy (≥10 drugs). The insulin regimen was categorized as basal only if it consisted of a long-acting insulin analogue or intermediate-acting insulin (ie, NPH (Neutral Protamine Hagedorn) insulin) alone, as pre-mixed if it consisted of pre-mixed insulins, and as basal-bolus (complex insulin regimen) if it consisted of a combination of long-acting or intermediate-acting insulin with short-acting insulin. The latter two regimens were considered 'complex' for the logistic regression analysis (see below). History of cardiovascular disease was defined as at least one of the following events having occurred: acute myocardial infarction, cerebrovascular event, transient ischemic attack and peripheral artery disease. Information on prior cardiovascular disease was assessed by the Rose questionnaire.[@R20] HbA~1c~ was reported according to the International Federation of Clinical Chemistry and Laboratory Medicine standard.[@R21] Tight glycemic control was defined as HbA~1c~ \<7% (53 mmol/mol). All measurements took place in certified on-site laboratories.[@R16]

Statistical analysis {#s2-6}
--------------------

Data were analyzed using IBM SPSS statistics V.25. Baseline descriptive analyses were expressed as mean±SD, proportion or median (25th and 75th percentiles). Student's independent two-sample t-tests and Pearson's χ^2^ tests were performed to examine differences between groups. We performed logistic regression analyses to examine the association between several demographic and clinical variables and IAH and severe hypoglycemia. The regression model for IAH and severe hypoglycemia were cumulatively adjusted for age, sex, diabetes duration, HbA~1c~, and for other variables that were significantly associated with the outcome in the crude analysis. A p value of \<0.05 was considered statistically significant.

Results {#s3}
=======

The Diabetes Pearl cohort consists of 7018 individuals.[@R16] After excluding participants who were not using insulin (n=4303) did not complete the Clarke questionnaire (n=226) or had too many missing data on the questionnaire (n=139), we included a total of 2350 patients with type 2 diabetes ([figure 1](#F1){ref-type="fig"}). There were 59.1% male participants, mean age was 61.1±10.4 years, mean diabetes duration 14.8±9.2 years and mean HbA~1c~ 7.9%±1.4% (62.5±14.8 mmol/mol). Almost 80% were on a complex insulin regimen ([online supplementary table S1](#SP1){ref-type="supplementary-material"}).
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Impaired awareness of hypoglycemia {#s3-1}
----------------------------------

The distribution of the modified Clarke score was highly skewed ([online supplementary figure S1](#SP1){ref-type="supplementary-material"}), with a total of 229 individuals (9.7%) having a score of ≥3 points, classifying them as having IAH. Clinical characteristics of the individuals with and without IAH are shown in [table 1](#T1){ref-type="table"}. There were no significant differences in the prevalence of IAH between men and women (10.2 vs 9.1%, p=NS) and between patients managed in primary or secondary/tertiary care (8.2 vs 10.4%, p=NS). Although glycemic control did not differ between individuals with or without IAH, the prevalence of IAH was significantly higher among individuals with tight glycemic control as compared with those with glycemic control that was less tight (p=0.046) ([figure 2](#F2){ref-type="fig"}, top). The presence of IAH was associated with complex insulin regimens, non-Caucasian ethnicity, lower BMI and not having a partner, and inversely with the use of sulfonylureas. After multivariate adjustment, complex insulin regimens, not having a partner and lower BMI were still associated with IAH ([table 2](#T2){ref-type="table"}). There were no statistical differences between the two groups concerning smoking, alcohol consumption, diabetes duration and use of beta-blockers or psychoactive drugs.

###### 

Clinical characteristics of people (n=2350) with or without IAH and severe hypoglycemia

  Characteristic                                IAH (n=229)           No IAH (n=2121)       Severe hypoglycemia (n=742)   No severe hypoglycemia (n=1608)
  --------------------------------------------- --------------------- --------------------- ----------------------------- ---------------------------------
  Sex (male)                                    142 (62.0)            1248 (58.8)           437 (58.9)                    953 (59.3)
  Age (years)                                   59.9±11.0             61.2±10.3             60.8±10.5                     61.2±10.3
  Clinical care                                                                                                           
   Primary care                                 55 (24.0)             614 (28.9)            185 (25.1)\*                  484 (30.2)
   Secondary/tertiary care                      173 (75.5)            1497 (70.6)           551 (74.9)\*                  1119 (69.8)
  Diabetes duration (years)                     15.5±9.7              14.7±9.1              15.7±9.4\*                    14.3±9.0
  HbA~1c~ (%) (mmol/mol)                        7.8±1.4 (61.4±15.3)   7.9±1.3 (62.6±14.7)   8.0±1.4 (63.7±15.5)           7.8±1.3 (62.0±14.4)
  Insulin treatment                                                                                                       
   Basal only                                   25 (10.9)†            453 (21.4)            106 (14.3)\*                  372 (23.1)
   Pre-mixed                                    40 (17.5)             339 (16.0)            122 (16.4)                    257 (16.0)
   Basal-bolus                                  163 (71.2)†           1327 (62.6)           513 (69.1)\*                  977 (60.8)
  Use of sulfonylureas                          12 (5.2)†             240 (11.3)            59 (8.0)\*                    193 (12.0)
  Use of metformin                              128 (55.9)            1324 (62.4)           423 (57.0)\*                  1029 (64.0)
  Pronounced polypharmacy                       73 (31.9)             632 (29.8)            263 (35.4)\*                  442 (27.5)
  Beta-blocker use                              86 (37.6)             859 (40.5)            298 (40.2)                    647 (40.2)
  Psychoactive drug use                         52 (22.7)             477 (22.5)            209 (28.2)\*                  320 (19.9)
  Ethnicity (Caucasian)                         169 (75.4)†           1714 (81.5)           565 (77.2)\*                  1318 (82.6)
  Partner (yes)                                 122 (63.2)†           1301 (73.5)           443 (72.0)                    980 (72.7)
  High educational level (yes)                  54 (23.8)             499 (23.6)            159 (21.6)                    394 (24.6)
  Current smoker (yes)                          47 (20.6)             389 (18.4)            145 (19.6)                    291 (18.2)
  High alcohol consumption (≥14 glasses/week)   15 (6.6)              132 (6.3)             49 (6.7)                      98 (6.2)
  BMI≥30 (kg/m^2^)                              112 (49.3)†           1198 (57.3)           410 (55.8)                    900 (56.9)
  History of cardiovascular disease (yes)       81 (35.4)             645 (30.4)            261 (35.2)\*                  465 (28.9)

Data are shown as number (%) or mean±SD. History of cardiovascular disease was defined as having ≥1 of the following; acute myocardial infarction, cerebrovascular event, transient ischemic attack, peripheral artery disease. Pronounced polypharmacy was defined as using ≥10 drugs.

\*p\<0.05 versus no SH.

†p\<0.05 versus no IAH

BMI, body mass index; IAH, impaired awareness of hypoglycemia; SH, severe hypoglycemia.

###### 

Logistic regression analyses to assess the association between variables and IAH in people with type 2 diabetes on insulin

  -------------------------------------------------------------------------------------------------------------------------
  Variable                  OR (95% CI)\            OR (95% CI)\            OR (95% CI)\            OR (95% CI)\
                            Crude analysis          Model 1                 Model 2                 Model 3
  ------------------------- ----------------------- ----------------------- ----------------------- -----------------------
  Caucasian ethnicity       **0.70 (0.51--0.97**)   0.73 (0.52--1.02)       **0.69 (0.48--0.99**)   0.76 (0.52--1.12)

  Having a partner          **0.62 (0.45--0.85**)   **0.60 (0.44--0.82**)   **0.59 (0.42--0.82**)   **0.59 (0.42--0.84**)

  BMI≥30 kg/m^2^            **0.73 (0.55--0.95**)   **0.72 (0.55--0.95**)   0.78 (0.58--1.06)       **0.71 (0.51--0.98**)

  Complex insulin regimen   **2.21 (1.44--3.39**)   **2.20 (1.43--3.38**)   **2.01 (1.29--3.16**)   **1.75 (1.06--2.88**)

  Use of sulfonylureas      **0.43 (0.24--0.79**)   **0.44 (0.24--0.81**)   **0.47 (0.25--0.88**)   0.62 (0.30--1.26)
  -------------------------------------------------------------------------------------------------------------------------

Statistically significant data (p\<0.05) appear in boldface type. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, HbA~1c~ and diabetes duration. Model 3 is adjusted for age, sex, HbA~1c~ and diabetes duration and for all other variables mentioned in [table 2](#T2){ref-type="table"}. Complex insulin regimen: a regimen consisting of pre-mixed insulin or combination of short-acting and intermediate-acting or long-acting insulin.

BMI, body mass index; IAH, impaired awareness of hypoglycemia.

![Proportion (%) of patients with IAH (top) or severe hypoglycemia (SH) (bottom) according to glycemic category, 7%=53 mmol/mol, 8%=64 mmol/mol, \*P value for trend \<0.05. IAH, impaired awareness of hypoglycemia.](bmjdrc-2019-000935f02){#F2}

Severe hypoglycemia {#s3-2}
-------------------

Severe hypoglycemia in the past 12 months was reported by 742 patients (31.6%), 193 (8.2%) of whom required medical intervention. The prevalence of severe hypoglycemia was similar across sex, but significantly higher among those with poorer glycemic control (p=0.016) ([figure 2](#F2){ref-type="fig"}, bottom). People with a history of severe hypoglycemia were more often non-Caucasian, had a longer diabetes duration, had a history of cardiovascular events, used psychoactive drugs and reported pronounced polypharmacy ([table 1](#T1){ref-type="table"}). Furthermore, people with severe hypoglycemia were more likely to use complex insulin regimens and less likely to use sulfonylureas or metformin, and were more often seen in secondary/tertiary care than in primary care centers when compared with people without severe hypoglycemia. However, after multivariate adjustment, the level of care was no longer associated with severe hypoglycemia and the same was true for use of sulfonylureas, pronounced polypharmacy and history of cardiovascular disease ([table 3](#T3){ref-type="table"}).

###### 

Logistic regression analyses to assess the association between variables and severe hypoglycemia in people with type 2 diabetes on insulin

  ------------------------------------------------------------------------------------------------------------------------------------
  Variable                             OR (95% CI)\            OR (95% CI)\            OR (95% CI)\            OR (95% CI)\
                                       Crude analysis          Model 1                 Model 2                 Model 3
  ------------------------------------ ----------------------- ----------------------- ----------------------- -----------------------
  Caucasian ethnicity                  **0.72 (0.58--0.89**)   **0.72 (0.58--0.90**)   **0.75 (0.60--0.96**)   **0.69 (0.54--0.88**)

  Clinical care (secondary/tertiary)   **1.29 (1.06--1.57**)   **1.28 (1.05--1.56**)   1.16 (0.93--1.44)       0.92 (0.72--1.16)

  Complex insulin regimen              **1.81 (1.43--2.29**)   **1.80 (1.42--2.28**)   **1.64 (1.27--2.12**)   **1.44 (1.07--1.94**)

  Use of sulfonylureas                 **0.63 (0.47--0.86**)   **0.64 (0.47--0.87**)   **0.68 (0.50--0.95**)   0.88 (0.60--1.27)

  Use of metformin                     **0.75 (0.63--0.89**)   **0.74 (0.62--0.88**)   **0.75 (0.62--0.91**)   **0.76 (0.62--0.93**)

  Pronounced polypharmacy              **1.45 (1.20--1.75**)   **1.48 (1.22--1.78**)   **1.40 (1.15--1.71**)   1.22 (0.97--1.54)

  Use of psychoactive drugs            **1.58 (1.29--1.93**)   **1.58 (1.29--1.94**)   **1.54 (1.24--1.91**)   **1.37 (1.08--1.75**)

  History of cardiovascular disease    **1.33 (1.11--1.61**)   **1.37 (1.13--1.65**)   **1.26 (1.03--1.54**)   1.17 (0.95--1.45)
  ------------------------------------------------------------------------------------------------------------------------------------

Statistically significant data (p\<0.05) appear in boldface type. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, HbA~1c~ and diabetes duration. Model 3 is adjusted for age, sex, HbA~1c~, diabetes duration and diabetes duration and for all other variables mentioned in [table 2](#T2){ref-type="table"}. Complex insulin regimen: a regimen consisting of pre-mixed insulin or combination of short-acting and intermediate- or long-acting insulin.

Conclusions {#s4}
===========

In this nationwide cohort of patients with type 2 diabetes treated with insulin, we found that the prevalence of IAH was 9.7% and that almost one out of three individuals reportedly experienced a severe hypoglycemic event in the preceding year. We observed that people not having a partner, with more complex insulin treatment regimens, use of psychoactive drugs, BMI \<30 kg/m^2^ and non-Caucasian descent were more susceptible for IAH or severe hypoglycemia. Interestingly, tight glycemic control was associated with a higher prevalence of IAH, but at the same time with a lower risk of severe hypoglycemia. Furthermore, the prevalence of severe hypoglycemia was significantly higher in secondary/tertiary care, but the association between level of care and severe hypoglycemia was no longer statistically significant after multivariate adjustment.

Our data on the prevalence of IAH in people with insulin-treated type 2 diabetes are in line with those reported in small studies using either the Gold score[@R6] or the Clarke questionnaire,[@R22] and extend these to a more general population of people with type 2 diabetes on insulin, including those from primary care. In accordance with previous findings, participants with IAH had somewhat tighter and those with severe hypoglycemia had somewhat poorer metabolic control.[@R13] Our data contrast with single-center surveys from Denmark[@R5] and Turkey[@R25] that reported IAH to vary between 31% and even 94% among people with type 2 diabetes on insulin. Part of this discrepancy may result from differences between questionnaires, thus potentially identifying different subgroups. We used the Dutch modified version of the Clarke questionnaire, which has been validated against hypoglycemic clamps in people with type 1 diabetes.[@R17] The methods by Gold and Clarke have a good mutual concordance and good predictability for biochemical hypoglycemia, but correlate less well with the method used in Denmark.[@R26] The latter method has been criticized for overestimating the prevalence of IAH.[@R26]

IAH was almost as prevalent in people with type 2 diabetes managed by primary care physicians as in those managed in secondary/tertiary care centers. The prevalence of severe hypoglycemia was slightly higher in secondary/tertiary care when compared with primary care. In fact, the association between type of care and severe hypoglycemia was completely lost after correction for age, sex, diabetes duration and HbA~1c~. Conversely, use of a complex insulin regimen increased the risk for both IAH and severe hypoglycemia, which was independent of where they received their care. The size and diversity of our cohort enabled us to also uncover non-Caucasian ethnicity and having no partner as independent new determinants of severe hypoglycemia and IAH, respectively, in people with type 2 diabetes, whereas we found no evidence for associations with smoking, as reported previously.[@R23]

Use of metformin was independently associated with lower odds of severe hypoglycemia in our population, which corroborates findings of a recent large cohort study.[@R28] The underlying mechanism explaining this observation remains to be determined. Metformin has been shown to modestly enhance the release of growth hormone during hypoglycemia, but not that of other counterregulatory hormones.[@R29] Alternatively, metformin-induced increases in plasma lactate may preserve brain function during hypoglycemia, thus potentially providing protection against severe hypoglycemia.[@R30] In univariate analysis, we also found an inverse relationship between use of sulfonylureas and IAH or severe hypoglycemia. Since particularly long-acting sulfonylureas are associated with increased risks of hypoglycemia,[@R32] this seemingly paradoxical finding is best explained by reverse causality. Indeed, it is highly likely that sulfonylureas were stopped after intensifying insulin therapy, in accordance with international guidelines,[@R34] or after experiencing severe or frequent hypoglycemic events, and not even commenced in patients thought to be at increased risk of hypoglycemia.

Our study has clinical implications as it shows that both IAH and severe hypoglycemia are common in people with type 2 diabetes on insulin therapy, even in those using basal insulin therapy alone or managed in primary care. Remarkably, although the prevalence of IAH in type 2 diabetes is at least twofold lower than what has been reported in type 1 diabetes, the occurrence of severe hypoglycemia was at least of the same magnitude.[@R10] A lack in education about hypoglycemia focused on this population may explain at least a part of this discrepancy. The symptomatology of hypoglycemia may differ in elderly people with type 2 diabetes, whereas those with type 1 diabetes are usually younger, have longer experience with insulin treatment and consequently may already have been educated more intensively and more frequently about hypoglycemia.[@R37] Some other risk factors for IAH in our study, for example non-Caucasian ethnicity, may also be partly explained by an educational gap. Focused education may reduce the burden of hypoglycemia and its potentially harmful consequences (eg, falls), as well as the associated risk of cardiovascular morbidity and mortality.[@R39]

Strengths of our study include the size of the cohort, being the largest to date in which the prevalence of IAH in type 2 diabetes has been determined and its national coverage due to the collaboration of all academic medical centers in the Netherlands. The inclusion of primary, secondary and tertiary care patients and the use of standardized protocols for data collection increase its generalizability. Our study also has limitations. Based on selection by academic centers, there may be an over-representation of complicated tertiary care patients. However, it should be noted that most previous studies also collected data in academic centers.[@R6] Second, the questionnaire we used to estimate IAH has not formally been validated in type 2 diabetes, but this applies to all questionnaires currently used for this purpose. Future research is needed to validate the questionnaire in patients with type 2 diabetes. Finally, we did not measure C-peptide values, the presence of which has been associated with lower hypoglycemia risks in people with type 1 diabetes,[@R42] and most data were collected before the widespread use of continuous glucose monitoring techniques.

In conclusion, IAH and severe hypoglycemia are relatively common among people with type 2 diabetes treated with insulin, particularly when managed with an intensified regimen, but independent of whether this is applied in primary, secondary or tertiary care. Greater awareness for IAH and severe hypoglycemia in people with type 2 diabetes on insulin is needed, with special attention for people without a partner or with non-Caucasian ethnicities. Appropriate education to reduce the risk of hypoglycemia in people with type 2 diabetes on insulin seems warranted, although this remains to be investigated.
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